Results 41 to 50 of about 2,816 (233)

177Lu-octreotate in Neuroendocrine Tumors: Treatment Effects [PDF]

, 2013
Neuroendocriene tumoren (NETs) zijn zeer zeldzame tumoren, die ontstaan vanuit neuroendocriene cellen in het lichaam. Deze tumoren produceren vaak hormonen en hormoonachtige stoffen.
Vliet, E.I. (Esther) van
core  

Nanodiamond Quantum Sensors for Probing Free Radical Biology

Advanced Functional Materials, EarlyView.
Free radicals play key roles in cellular signaling and disease but remain difficult to measure in living systems. Nanodiamonds (NDs) with nitrogen‐vacancy (NV) centers enable quantum sensing of local magnetic noise via T₁ relaxometry, providing nondestructive radical detection in living cells.
Qi Lu, Yingke Wu, Tanja Weil
wiley   +1 more source

Peptide Receptor Radionuclide Therapy with 177Lu-octreotate: clinical aspects [PDF]

, 2012
Somatostatin is a neuropeptide with a variety of functions and is produced in several tissues. The isoform somatostatin-14 (SS-14) is more biologically active than SS-28.
Essen, M. (Martijn) van
core  

The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review [PDF]

, 2016
Introduction: While the majority of the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors currently used for the therapy of metastatic renal cell carcinoma (mRCC) are small molecule agents inhibiting multiple ...
Aieta, Michele, Ascione, Ilaria, Bosso, Davide, Buonerba, Carlo, Caraglia, Michele, De Cobelli, Ottavio, De Placido, Sabino, Di Lorenzo, Giuseppe, Facchini, Gaetano, Ferro, Matteo, Lucarelli, Giuseppe, Pagliuca, Martina, Pignataro, Piero, Puglia, Livio, Rossetti, Sabrina, Sonpavde, Guru, Terracciano, Daniela   +16 more
core   +1 more source

Atomic Layer Deposition in Transistors and Monolithic 3D Integration

Advanced Functional Materials, EarlyView.
Transistors are fundamental building blocks of modern electronics. This review summarizes recent progress in atomic layer deposition (ALD) for the synthesis of two‐dimensional (2D) metal oxides and transition‐metal dichalcogenides (TMDCs), with particular emphasis on their enabling role in monolithic three‐dimensional (M3D) integration for next ...
Yue Liu, Taoyu Zou, Cheng‐Yan Xu, Liang Zhen, Yang Li, Yong‐Young Noh   +5 more
wiley   +1 more source

Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters

EJNMMI Radiopharmacy and Chemistry
Background Lutetium-177 (177Lu) theranostics have revolutionized personalized cancer treatment, particularly with FDA-approved therapies like [177Lu]Lu-DOTA-TATE for neuroendocrine tumors and [177Lu]Lu-PSMA for prostate cancer.
William Hunt, Mathew Long, Usama Kamil, Sunil Kellapatha, Wayne Noonan, Peter D. Roselt, Nathan Papa, Brittany Emmerson, Michael S. Hofman, Mohammad B. Haskali   +9 more
doaj   +1 more source

Toxicity Assessment of [¹⁷⁷Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes

Nanomaterials, 2022
The fibroblast activation protein (FAP) is heavily expressed in fibroblasts associated with the tumor microenvironment, while the prostate-specific membrane antigen (PSMA) is expressed in the neovasculature of malignant angiogenic processes.
Tania Hernández-Jiménez, Pedro Cruz-Nova, Alejandra Ancira-Cortez, Brenda Gibbens-Bandala, Nancy Lara-Almazán, Blanca Ocampo-García, Clara Santos-Cuevas, Enrique Morales-Avila, Guillermina Ferro-Flores   +8 more
doaj   +1 more source

Computational Modeling Meets 3D Bioprinting: Emerging Synergies in Cardiovascular Disease Modeling

Advanced Healthcare Materials, EarlyView.
Emerging advances in three‐dimensional bioprinting and computational modeling are reshaping cardiovascular (CV) research by enabling more realistic, patient‐specific tissue platforms. This review surveys cutting‐edge approaches that merge biomimetic CV constructs with computational simulations to overcome the limitations of traditional models, improve ...
Tanmay Mukherjee, Mehdi Salar Amoli, Sarah Rezapourdamanab, Lama Rita El Shammas, Martin L. Tomov, Emilio A. Mendiola, Vahid Serpooshan, Reza Avazmohammadi   +7 more
wiley   +1 more source

Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit

BJC Reports
In the PSMAfore randomized controlled trial patients with chemotherapy naïve castrate resistant metastasized prostate cancer (CRPC) progressing after one line of a second-generation androgen receptor signaling inhibitor (ARSI) were randomized to the ...
J. B. Schnog, A. J. Duits, M. J. Samson
doaj   +1 more source

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials

Therapeutic Advances in Medical Oncology, 2023
Metastatic prostate cancer continues to be an incurable disease. Despite all the novel therapies approved in the past two decades, overall patient outcomes remain relatively poor, and these patients die on a regular basis.
Albert Jang, Ayse T. Kendi, Oliver Sartor   +2 more
doaj   +1 more source